PT-141 10 MG - VIAL

RESEARCH USE PROTOCOL

Reconstitution	Reconstitute by adding 2 mL of bacteriostatic water to the vial
Dosage	Initial dose: Draw 20 units; wait 30 minutes to assess response. If well tolerated, administer an additional 20 units.
Time of Day	AM or PM
Injection Type	Subcutaneous (abdomen, thigh, or upper arm) Can be administered intramuscularly (IM) if experiencing redness, itching, or swelling at the injection site.
Product Details	Concentration: 10 mg / 2 mL
Product Duration	One vial contains 5 doses
Program Duration	Use as needed, based on individual requirements
Storage	Store refrigerated at 2–8°C (36–46°F). Do not freeze. Protect from light.

WHAT IS PT-141 ?

PT-141 (Bremelanotide) is a peptide that works by activating melanocortin receptors in the brain involved in sexual arousal and desire. Unlike medications that act on blood flow, PT-141 works through the central nervous system, helping stimulate natural arousal pathways.

PT-141 is commonly used to support libido, sexual desire, and performance in both men and women.

WHAT'S IN THE BOX?

HOW IT WORKS

MECHANISM OF ACTION

PT-141 is studied for its ability to activate melanocortin receptors (MC3R and MC4R), which are associated with regulating arousal and behavioral response:

- Activates neural pathways related to arousal
- Supports libido and sexual motivation signals
- Associated with central (non-vascular) response mechanisms
- May influence behavioral response patterns

These mechanisms are linked to neurological signaling rather than circulatory pathways.

RESEARCH OBSERVATIONS

- Studied for libido-related pathways
- Studied for arousal response mechanisms
- Studied for behavioral response modulation
- Studied for neurological signaling pathways

OBSERVED REACTIONS IN RESEARCH SETTINGS

Research observations have noted mild and temporary responses such as flushing, nausea, headache, or localized irritation. Responses may vary depending on protocol design and individual variability.

RESEARCH NOTES

In research settings, timing of administration may influence observed response patterns. Factors such as dosage, frequency, and environmental conditions may affect outcomes. Individual variability should be considered when interpreting results.

IMPORTANT CONSIDERATIONS FOR RESEARCH USE

- Not intended for human consumption or therapeutic use
- Not suitable for use during pregnancy or breastfeeding
- Not recommended for individuals with uncontrolled cardiovascular conditions
- Use in research settings may require professional oversight
- Not for use alongside medical treatments without supervision
- Individual variability may influence observed outcomes